Evidence map›Paper›PMID 34979103›Full record

ArticleJournal of molecular and cellular cardiology2022

Epigallocatechin gallate facilitates extracellular elastin fiber formation in induced pluripotent stem cell derived vascular smooth muscle cells for tissue engineering.

Matthew W Ellis, Muhammad Riaz, Yan Huang, Christopher W Anderson, Jiesi Luo, Jinkyu Park, Colleen A Lopez, Luke D Batty, Kimberley H Gibson, Yibing Qyang

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Use of iPSC-Derived Smooth Muscle Cells to Model Physiology and Pathology.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Matthew W EllisYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Cellular and Molecular Physiology, Yale University, New Haven, CT 06519, USA.
Muhammad RiazYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Yan HuangYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Christopher W AndersonYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Pathology, Yale University, New Haven, CT 06520, USA.
Jiesi LuoYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Jinkyu ParkYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Colleen A LopezYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA.
Luke D BattyYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Pathology, Yale University, New Haven, CT 06520, USA.
Kimberley H GibsonCenter for Cellular and Molecular Imaging: Electron Microscopy, Department of Cell Biology, Yale School of Medicine, New Haven, CT 06520, USA.
Yibing QyangYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Pathology, Yale University, New Haven, CT 06520, USA; Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: yibing.qyang@yale.edu.
Yale Cancer Center · USYale University · US

Funding

Vascular Training GrantT32HL007950 · NHLBI · YALE UNIVERSITY · PI JEFFREY R. BENDER, Daniel Greif · 2000 to 2026
$9.6M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical CareR01HL150352 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2020 to 2023
$2.8M
Human tissue-engineered blood vessels using induced pluripotent stem cellsR01HL116705 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2013 to 2017
$2.0M
Development of HLA engineered universal vascular grafts from human iPSCsR01HL155411 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2021 to 2024
$1.7M
HUMAN TISSUE ENGINEERED PULSATILE CONDUITS USING ENGINEERED HEART TISSUE OF DEFINED COMPOSITION AND FIBER ORIENTATIONF31HL143928 · NHLBI · YALE UNIVERSITY · PI ANDERSON, CHRISTOPHER W · 2018 to 2020
$135k
PRODUCING PIG INDUCED PLURIPOTENT STEM CELLS FOR CARDIOVASCULAR TISSUE ENGINEERINGF31HL149289 · NHLBI · YALE UNIVERSITY · PI BATTY, LUKE DANIEL · 2019 to 2021
$126k
Biomechanical Signaling in Vascular Smooth Muscle Cell Proliferative Disease Following Functional Loss of ElastinF31HL143924 · NHLBI · YALE UNIVERSITY · PI ELLIS, MATTHEW W · 2019 to 2020
$91k
NHLBI NIH HHS F31 HL143924NHLBI NIH HHS F31 HL143928NHLBI NIH HHS F31 HL149289NHLBI NIH HHS R01 HL116705NHLBI NIH HHS R01 HL150352NHLBI NIH HHS R01 HL155411NHLBI NIH HHS T32 HL007950NIGMS NIH HHS T32 GM007324
6 · The paper itself

Abstract

Tissue engineered vascular grafts possess several advantages over synthetic or autologous grafts, including increased availability and reduced rates of infection and thrombosis. Engineered grafts constructed from human induced pluripotent stem cell derivatives further offer enhanced reproducibility in graft production. One notable obstacle to clinical application of these grafts is the lack of elastin in the vessel wall, which would serve to endow compliance in addition to mechanical strength. This study establishes the ability of the polyphenol compound epigallocatechin gallate, a principal component of green tea, to facilitate the extracellular formation of elastin fibers in vascular smooth muscle cells derived from human induced pluripotent stem cells. Further, this study describes the creation of a doxycycline-inducible elastin expression system to uncouple elastin production from vascular smooth muscle cell proliferative capacity to permit fiber formation in conditions conducive to robust tissue engineering.

Indexed as

Induced Pluripotent Stem CellsTissue EngineeringCatechinElastinHumansMuscle, Smooth, VascularMyocytes, Smooth MuscleReproducibility of ResultsCatechinElastinepigallocatechin gallateElastinEpigallocatechin gallatehiPSCsTissue engineering

Identifiers

PMID34979103
PMCPMC8920537
OpenAlexW4205947820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.